LIFE SAVING DRUGS PROGRAM EXPERT PANEL

TENTH MEETING: 8 October 2021

**AGENDA**

1. **Standing business**
   1. Welcome and apologies
   2. Declaration of potential or actual Conflicts of Interest
   3. Correspondence
   4. Report from the Secretariat
2. **Reviews of existing LSDP medicines**

24 month reviews – discussion of **draft** reports

* 1. Migalastat (Galafold®) - for the treatment of Fabry Disease
  2. Cerliponase alfa (Brineura®) – for the treatment of Late Infantile Onset Batten (CLN2) Disease

1. **Applications for new LSDP medicines**
   1. Asfotase alfa (Strensiq®) – for the treatment of perinatal and infantile-onset hypophophatasia
2. **Other business**